<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34342728</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1534-3170</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current cardiology reports</Title>
          <ISOAbbreviation>Curr Cardiol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications.</ArticleTitle>
        <Pagination>
          <StartPage>129</StartPage>
          <MedlinePgn>129</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">129</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11886-021-01551-x</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">In coronavirus disease 2019 (COVID-19), myocardial injury occurs frequently in severe or critically ill hospitalized patients, yet myocarditis is much less common. In this context, revisiting the definition of myocarditis is appropriate with a specific focus on diagnostic and management considerations in patients infected with SARS-CoV-2.</AbstractText>
          <AbstractText Label="RECENT FINDINGS">Pathologic cardiac specimens from patients with COVID-19 suggest a mixed inflammatory response involving lymphocytes and macrophages, and importantly, cellular injury occurs predominantly at the level of pericytes and endothelial cells, less often involving direct myocyte necrosis. In COVID-19, the diagnosis of myocarditis has understandably been based predominantly on clinical criteria, and the number of patients with clinically suspected myocarditis who would meet diagnostic histological criteria is unclear. Echocardiography and cardiac magnetic resonance are important diagnostic tools, although the prognostic implications of abnormalities are still being defined. Importantly, SARS-CoV2 myocarditis should be diagnosed within an appropriate clinical context and should not be based on isolated imaging findings. Therapies in COVID-19 have focused on the major clinical manifestation of pneumonia, but the promotion of viral clearance early in the disease could prevent the development of myocarditis, and further study of immunosuppressive therapies once myocarditis has developed are indicated. A strict and uniform approach is needed to diagnose myocarditis due to SARS-CoV-2 to better understand the natural history of this disease and to facilitate evaluation of potential therapeutic interventions. A methodological approach will also better inform the incidence of COVID-19 associated myocarditis and potential long-term health effects.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abou Hassan</LastName>
            <ForeName>Ossama K</ForeName>
            <Initials>OK</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sheng</LastName>
            <ForeName>Calvin C</ForeName>
            <Initials>CC</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Tom Kai Ming</ForeName>
            <Initials>TKM</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cremer</LastName>
            <ForeName>Paul C</ForeName>
            <Initials>PC</Initials>
            <Identifier Source="ORCID">0000-0002-0794-3306</Identifier>
            <AffiliationInfo>
              <Affiliation>Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. cremerp@ccf.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Cardiol Rep</MedlineTA>
        <NlmUniqueID>100888969</NlmUniqueID>
        <ISSNLinking>1523-3782</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">COVID-19 therapy</Keyword>
        <Keyword MajorTopicYN="Y">Myocardial injury</Keyword>
        <Keyword MajorTopicYN="Y">Myocarditis</Keyword>
        <Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
      </KeywordList>
      <CoiStatement>Dr. Wang reports grants from National Heart Foundation of New Zealand, outside the submitted work. Dr. Cremer reports grants from Novartis Pharmaceuticals and Kiniksa Pharmaceuticals; and personal fees from Kiniksa Pharmaceuticals and Sobi Pharmaceuticals, outside the submitted work. The other authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>3</Day>
          <Hour>12</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34342728</ArticleId>
        <ArticleId IdType="pmc">PMC8330199</ArticleId>
        <ArticleId IdType="doi">10.1007/s11886-021-01551-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s11886-021-01551-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Huber SA, Gauntt CJ, Sakkinen P. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv Virus Res [Internet] 1998;51:35–80. doi: 10.1016/S0065-3527(08)60783-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-3527(08)60783-6</ArticleId>
            <ArticleId IdType="pubmed">9891585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, et al.  Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A [Internet] 1992;89:314–318. doi: 10.1073/pnas.89.1.314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.89.1.314</ArticleId>
            <ArticleId IdType="pmc">PMC48227</ArticleId>
            <ArticleId IdType="pubmed">1309611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malkiel S, Kuan AP, Diamond B. Autoimmunity in heart disease: mechanisms and genetic susceptibility. Mol Med Today [Internet] 1996;2:336–342. doi: 10.1016/1357-4310(96)81799-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1357-4310(96)81799-0</ArticleId>
            <ArticleId IdType="pubmed">8796919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, et al.  A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J [Internet] 2007;28:1326–1333. doi: 10.1093/eurheartj/ehm076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehm076</ArticleId>
            <ArticleId IdType="pubmed">17493945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al.  Predictors of outcome in patients with suspected myocarditis. Circulation [Internet] 2008;118:639–648. doi: 10.1161/CIRCULATIONAHA.108.769489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.769489</ArticleId>
            <ArticleId IdType="pubmed">18645053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al.  Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation [Internet] 2004;109:1250–1258. doi: 10.1161/01.CIR.0000118493.13323.81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000118493.13323.81</ArticleId>
            <ArticleId IdType="pubmed">14993139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bock C-T, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med [Internet] 2010;362:1248–1249. doi: 10.1056/NEJMc0911362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc0911362</ArticleId>
            <ArticleId IdType="pubmed">20357294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart Int. 1997;78:539–543. doi: 10.1136/hrt.78.6.539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/hrt.78.6.539</ArticleId>
            <ArticleId IdType="pmc">PMC1892342</ArticleId>
            <ArticleId IdType="pubmed">9470867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maisch B, Schönian U, Crombach M, Wendl I, Bethge C, Herzum M, et al.  Cytomegalovirus associated inflammatory heart muscle disease. Scand J Infect Dis Suppl [Internet] 1993;88:135–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8390717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al.  High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation [Internet] 2005;111:887–893. doi: 10.1161/01.CIR.0000155616.07901.35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000155616.07901.35</ArticleId>
            <ArticleId IdType="pubmed">15699250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander LK, Keene BW, Small JD, Yount B, Baric RS. Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy. Adv Exp Med Biol [Internet] 1993;342:365–370. doi: 10.1007/978-1-4615-2996-5_56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4615-2996-5_56</ArticleId>
            <ArticleId IdType="pubmed">8209755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC COVID-19 Response Team  Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep [Internet] 2020;69:343–346. doi: 10.15585/mmwr.mm6912e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15585/mmwr.mm6912e2</ArticleId>
            <ArticleId IdType="pmc">PMC7725513</ArticleId>
            <ArticleId IdType="pubmed">32214079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol [Internet] 2020;5:802–810. doi: 10.1001/jamacardio.2020.0950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId>
            <ArticleId IdType="pmc">PMC7097841</ArticleId>
            <ArticleId IdType="pubmed">32211816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) JAMA Cardiol [Internet] 2020;5:811–818. doi: 10.1001/jamacardio.2020.1017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId>
            <ArticleId IdType="pmc">PMC7101506</ArticleId>
            <ArticleId IdType="pubmed">32219356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic to Transl Sci [Internet] 2020;5:518–536. doi: 10.1016/j.jacbts.2020.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacbts.2020.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC7151394</ArticleId>
            <ArticleId IdType="pubmed">32292848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akhmerov A, Marbán E. COVID-19 and the Heart. Circ Res [Internet] 2020;126:1443–1455. doi: 10.1161/CIRCRESAHA.120.317055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317055</ArticleId>
            <ArticleId IdType="pmc">PMC7188058</ArticleId>
            <ArticleId IdType="pubmed">32252591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pericàs JM, Hernandez-Meneses M, Sheahan TP, Quintana E, Ambrosioni J, Sandoval E, et al.  COVID-19: from epidemiology to treatment. Eur Heart J [Internet] 2020;41:2092–2112. doi: 10.1093/eurheartj/ehaa462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehaa462</ArticleId>
            <ArticleId IdType="pmc">PMC7279517</ArticleId>
            <ArticleId IdType="pubmed">32511724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. J Card Fail [Internet] 2020;26:470–475. doi: 10.1016/j.cardfail.2020.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cardfail.2020.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC7166030</ArticleId>
            <ArticleId IdType="pubmed">32315733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med [Internet]. 2020; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32678530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7383595</ArticleId>
            <ArticleId IdType="pubmed">32678530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.  Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med [Internet] 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId>
            <ArticleId IdType="pmc">PMC7262788</ArticleId>
            <ArticleId IdType="pubmed">32445440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation [Internet] 1996;93:841–842. doi: 10.1161/01.CIR.93.5.841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.93.5.841</ArticleId>
            <ArticleId IdType="pubmed">8598070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, et al.  Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol [Internet] 1987;1:3–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3455232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc [Internet] 1989;64:1235–1245. doi: 10.1016/S0025-6196(12)61286-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0025-6196(12)61286-5</ArticleId>
            <ArticleId IdType="pubmed">2593714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol [Internet] 1989;14:915–920. doi: 10.1016/0735-1097(89)90465-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0735-1097(89)90465-8</ArticleId>
            <ArticleId IdType="pubmed">2794278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu LA, Lapeyre AC, Cooper LT. Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis. Mayo Clin Proc [Internet] 2001;76:1030–1038. doi: 10.4065/76.10.1030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/76.10.1030</ArticleId>
            <ArticleId IdType="pubmed">11605687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation [Internet] 2006;113:593–595. doi: 10.1161/CIRCULATIONAHA.105.589663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.589663</ArticleId>
            <ArticleId IdType="pubmed">16449736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med [Internet] 1995;333:269–275. doi: 10.1056/NEJM199508033330501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199508033330501</ArticleId>
            <ArticleId IdType="pubmed">7596370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J [Internet] 2013;34:2636–2648. doi: 10.1093/eurheartj/eht210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/eht210</ArticleId>
            <ArticleId IdType="pubmed">23824828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet (London, England) [Internet] 2012;379:738–747. doi: 10.1016/S0140-6736(11)60648-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(11)60648-X</ArticleId>
            <ArticleId IdType="pmc">PMC5814111</ArticleId>
            <ArticleId IdType="pubmed">22185868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al.  Cardiovascular magnetic resonance in myocarditis: A a JACC White Paper. J Am Coll Cardiol [Internet] 2009;53:1475–1487. doi: 10.1016/j.jacc.2009.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2009.02.007</ArticleId>
            <ArticleId IdType="pmc">PMC2743893</ArticleId>
            <ArticleId IdType="pubmed">19389557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al.  Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol [Internet] 2018;72:3158–3176. doi: 10.1016/j.jacc.2018.09.072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2018.09.072</ArticleId>
            <ArticleId IdType="pubmed">30545455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, et al.  Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging [Internet] 2012;5:513–524. doi: 10.1016/j.jcmg.2011.11.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmg.2011.11.022</ArticleId>
            <ArticleId IdType="pubmed">22595159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al.  Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. J Am Coll Cardiol [Internet] 2016;67:1800–1811. doi: 10.1016/j.jacc.2016.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2016.02.013</ArticleId>
            <ArticleId IdType="pubmed">27081020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumm J, Greulich S, Wagner A, Grün S, Ong P, Bentz K, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson [Internet]. 2014;(16):14 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24461053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3913958</ArticleId>
            <ArticleId IdType="pubmed">24461053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kadkhodayan A, Chareonthaitawee P, Raman SV, Cooper LT. Imaging of Inflammation in Unexplained Cardiomyopathy. JACC Cardiovasc Imaging [Internet] 2016;9:603–617. doi: 10.1016/j.jcmg.2016.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmg.2016.01.010</ArticleId>
            <ArticleId IdType="pubmed">27151523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermes E, Childs H, Faris P, Friedrich MG. Predictive value of CMR criteria for LV functional improvement in patients with acute myocarditis. Eur Heart J Cardiovasc Imaging [Internet] 2014;15:1140–1144. doi: 10.1093/ehjci/jeu099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ehjci/jeu099</ArticleId>
            <ArticleId IdType="pubmed">24925145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bohnen S, Radunski UK, Lund GK, Tahir E, Avanesov M, Stehning C, et al.  T1 mapping cardiovascular magnetic resonance imaging to detect myocarditis-Impact of slice orientation on the diagnostic performance. Eur J Radiol [Internet] 2017;86:6–12. doi: 10.1016/j.ejrad.2016.10.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejrad.2016.10.031</ArticleId>
            <ArticleId IdType="pubmed">28027767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Knobelsdorff-Brenkenhoff F, Schüler J, Dogangüzel S, Dieringer MA, Rudolph A, Greiser A, et al.  Detection and Monitoring of Acute Myocarditis Applying Quantitative Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging [Internet] 2017;10:e005242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28213448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotanidis CP, Bazmpani M-A, Haidich A-B, Karvounis C, Antoniades C, Karamitsos TD. Diagnostic Accuracy of Cardiovascular Magnetic Resonance in Acute Myocarditis: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging [Internet] 2018;11:1583–1590. doi: 10.1016/j.jcmg.2017.12.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmg.2017.12.008</ArticleId>
            <ArticleId IdType="pubmed">29454761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan JA, Lee YJ, Salerno M. Diagnostic Performance of Extracellular Volume, Native T1, and T2 Mapping Versus Lake Louise Criteria by Cardiac Magnetic Resonance for Detection of Acute Myocarditis: A Meta-Analysis. Circ Cardiovasc Imaging [Internet] 2018;11:e007598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6192699</ArticleId>
            <ArticleId IdType="pubmed">30012826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schultheiss H-P, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J [Internet] 2011;32:2616–2625. doi: 10.1093/eurheartj/ehr165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehr165</ArticleId>
            <ArticleId IdType="pubmed">21705357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knowlton KU. CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol [Internet] 2008;323:315–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18357777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wessely R, Klingel K, Santana LF, Dalton N, Hongo M, Jonathan Lederer W, et al.  Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest [Internet] 1998;102:1444–1453. doi: 10.1172/JCI1972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI1972</ArticleId>
            <ArticleId IdType="pmc">PMC508992</ArticleId>
            <ArticleId IdType="pubmed">9769337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, et al.  Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation [Internet] 2013;128:42–49. doi: 10.1161/CIRCULATIONAHA.113.001531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.001531</ArticleId>
            <ArticleId IdType="pubmed">23709669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foerster SR, Canter CE, Cinar A, Sleeper LA, Webber SA, Pahl E, et al.  Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry. Circ Heart Fail [Internet] 2010;3:689–697. doi: 10.1161/CIRCHEARTFAILURE.109.902833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.109.902833</ArticleId>
            <ArticleId IdType="pubmed">20833772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarez JA, Orav EJ, Wilkinson JD, Fleming LE, Lee DJ, Sleeper LA, et al.  Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. Circulation [Internet] 2011;124:814–823. doi: 10.1161/CIRCULATIONAHA.110.973826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.973826</ArticleId>
            <ArticleId IdType="pmc">PMC3199969</ArticleId>
            <ArticleId IdType="pubmed">21788591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al.  Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. Circulation [Internet] 2018;138:1088–1099. doi: 10.1161/CIRCULATIONAHA.118.035319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035319</ArticleId>
            <ArticleId IdType="pubmed">29764898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio AL, Goldman JH, Haven AJ, Baig KM, Libera LD, McKenna WJ. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators. Eur Heart J [Internet] 1997;18:270–275. doi: 10.1093/oxfordjournals.eurheartj.a015230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.eurheartj.a015230</ArticleId>
            <ArticleId IdType="pubmed">9043844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauer B, Schannwell M, Kühl U, Strauer BE, Schultheiss HP. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol [Internet] 2000;35:11–18. doi: 10.1016/S0735-1097(99)00485-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0735-1097(99)00485-4</ArticleId>
            <ArticleId IdType="pubmed">10636253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio ALP, Vinci A, Iliceto S. Anti-heart autoantibodies in familial dilated cardiomyopathy. Autoimmunity [Internet] 2008;41:462–469. doi: 10.1080/08916930802031546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08916930802031546</ArticleId>
            <ArticleId IdType="pubmed">18781472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT. Myocarditis. N Engl J Med [Internet] 2009;360:1526–1538. doi: 10.1056/NEJMra0800028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0800028</ArticleId>
            <ArticleId IdType="pmc">PMC5814110</ArticleId>
            <ArticleId IdType="pubmed">19357408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, et al.  Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation [Internet] 2005;112:1965–1970. doi: 10.1161/CIRCULATIONAHA.105.548156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.548156</ArticleId>
            <ArticleId IdType="pubmed">16172268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al.  Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol [Internet] 2012;59:1604–1615. doi: 10.1016/j.jacc.2012.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2012.01.007</ArticleId>
            <ArticleId IdType="pubmed">22365425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barone-Rochette G, Augier C, Rodière M, Quesada J-L, Foote A, Bouvaist H, et al.  Potentially simple score of late gadolinium enhancement cardiac MR in acute myocarditis outcome. J Magn Reson Imaging [Internet] 2014;40:1347–1354. doi: 10.1002/jmri.24504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmri.24504</ArticleId>
            <ArticleId IdType="pubmed">24293405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K, et al.  Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol [Internet] 2017;70:1964–1976. doi: 10.1016/j.jacc.2017.08.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2017.08.050</ArticleId>
            <ArticleId IdType="pmc">PMC6506846</ArticleId>
            <ArticleId IdType="pubmed">29025553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezkalla S, Kloner RA, Khatib G, Khatib R. Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis. Am Heart J [Internet] 1990;120:1377–1381. doi: 10.1016/0002-8703(90)90251-R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-8703(90)90251-R</ArticleId>
            <ArticleId IdType="pubmed">2174203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice. Circulation [Internet] 1991;83:2021–2028. doi: 10.1161/01.CIR.83.6.2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.83.6.2021</ArticleId>
            <ArticleId IdType="pubmed">1674900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis Associated with Influenza A H1N1pdm2009. Influenza Res Treat [Internet] 2012;2012:351979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3533457</ArticleId>
            <ArticleId IdType="pubmed">23304476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose NR, Neumann DA, Herskowitz A. Coxsackievirus myocarditis. Adv Intern Med [Internet] 1992;37:411–429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1558005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol [Internet] 1988;12:1334–1341. doi: 10.1016/0735-1097(88)92618-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0735-1097(88)92618-6</ArticleId>
            <ArticleId IdType="pubmed">2844874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kishimoto C, Crumpacker CS, Abelmann WH. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D, Cardiovasc Res [Internet]. 1988;22:732–8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/2855719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2855719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J [Internet] 1988;115:1229–1232. doi: 10.1016/0002-8703(88)90013-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-8703(88)90013-0</ArticleId>
            <ArticleId IdType="pubmed">2837073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio ALP, Angelini A, Blank M, Shani A, Kivity S, Goddard G, et al.  Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. Int J Cardiol [Internet] 2015;179:166–177. doi: 10.1016/j.ijcard.2014.10.165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2014.10.165</ArticleId>
            <ArticleId IdType="pubmed">25464438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padalko E, Verbeken E, Matthys P, Aerts JL, De Clercq E, Neyts J. Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol [Internet] 2003;3:25. doi: 10.1186/1471-2180-3-25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2180-3-25</ArticleId>
            <ArticleId IdType="pmc">PMC317291</ArticleId>
            <ArticleId IdType="pubmed">14687413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomioka N, Kishimoto C, Matsumori A, Kawai C. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol [Internet] 1986;7:868–872. doi: 10.1016/S0735-1097(86)80349-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0735-1097(86)80349-7</ArticleId>
            <ArticleId IdType="pubmed">3007597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monrad ES, Matsumori A, Murphy JC, Fox JG, Crumpacker CS, Abelmann WH. Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. Circulation [Internet] 1986;73:1058–1064. doi: 10.1161/01.CIR.73.5.1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.73.5.1058</ArticleId>
            <ArticleId IdType="pubmed">3698228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>London RS, Bradley L, Chiamori NY. Effect of a nutritional supplement on premenstrual symptomatology in women with premenstrual syndrome: a double-blind longitudinal study. J Am Coll Nutr [Internet] 1991;10:494–499. doi: 10.1080/07315724.1991.10718176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07315724.1991.10718176</ArticleId>
            <ArticleId IdType="pubmed">1955626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, et al.  Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation [Internet] 2001;104:39–45. doi: 10.1161/01.CIR.104.1.39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.104.1.39</ArticleId>
            <ArticleId IdType="pubmed">11435335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson JL, Hartling L, Crumley E, Vandermeer B, Klassen TP. A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord [Internet] 2005;5:12. doi: 10.1186/1471-2261-5-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2261-5-12</ArticleId>
            <ArticleId IdType="pmc">PMC1173096</ArticleId>
            <ArticleId IdType="pubmed">15932639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C-M, Wong RS-M, Wu EB, Kong S-L, Wong J, Yip GW-K, et al.  Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J [Internet] 2006;82:140–144. doi: 10.1136/pgmj.2005.037515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/pgmj.2005.037515</ArticleId>
            <ArticleId IdType="pmc">PMC2596695</ArticleId>
            <ArticleId IdType="pubmed">16461478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med [Internet] 2016;36:78–80. doi: 10.5144/0256-4947.2016.78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5144/0256-4947.2016.78</ArticleId>
            <ArticleId IdType="pmc">PMC6074274</ArticleId>
            <ArticleId IdType="pubmed">26922692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA [Internet] 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId>
            <ArticleId IdType="pmc">PMC7042881</ArticleId>
            <ArticleId IdType="pubmed">32031570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al.  Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol [Internet] 2020;76:533–546. doi: 10.1016/j.jacc.2020.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2020.06.007</ArticleId>
            <ArticleId IdType="pmc">PMC7279721</ArticleId>
            <ArticleId IdType="pubmed">32517963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) [Internet] 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irabien-Ortiz Á, Carreras-Mora J, Sionis A, Pàmies J, Montiel J, Tauron M. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol (Engl Ed) [Internet] 2020;73:503–504. doi: 10.1016/j.recesp.2020.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.recesp.2020.04.001</ArticleId>
            <ArticleId IdType="pmc">PMC7158782</ArticleId>
            <ArticleId IdType="pubmed">32345547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul J-F, Charles P, Richaud C, Caussin C, Diakov C. Myocarditis revealing COVID-19 infection in a young patient. Eur Heart J Cardiovasc Imaging [Internet] 2020;21:776. doi: 10.1093/ehjci/jeaa107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ehjci/jeaa107</ArticleId>
            <ArticleId IdType="pmc">PMC7197601</ArticleId>
            <ArticleId IdType="pubmed">32338706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lara D, Young T, Del Toro K, Chan V, Ianiro C, Hunt K, et al.  Acute Fulminant Myocarditis in a Pediatric Patient With COVID-19 Infection. Pediatr Int. 2020;146:e20201509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32747591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al.  Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail [Internet] 2020;22:911–915. doi: 10.1002/ejhf.1828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.1828</ArticleId>
            <ArticleId IdType="pmc">PMC7262276</ArticleId>
            <ArticleId IdType="pubmed">32275347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al.  Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol [Internet] 2020;33:1007–1014. doi: 10.1038/s41379-020-0536-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41379-020-0536-x</ArticleId>
            <ArticleId IdType="pmc">PMC7156231</ArticleId>
            <ArticleId IdType="pubmed">32291399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol [Internet] 2020;153:725–733. doi: 10.1093/ajcp/aqaa062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ajcp/aqaa062</ArticleId>
            <ArticleId IdType="pmc">PMC7184436</ArticleId>
            <ArticleId IdType="pubmed">32275742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.  Endothelial cell infection and endotheliitis in COVID-19. Lancet (London, England) [Internet] 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId>
            <ArticleId IdType="pmc">PMC7172722</ArticleId>
            <ArticleId IdType="pubmed">32325026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med [Internet] 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId>
            <ArticleId IdType="pmc">PMC7164771</ArticleId>
            <ArticleId IdType="pubmed">32085846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol [Internet] 2020;5:1281–1285. doi: 10.1001/jamacardio.2020.3551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2020.3551</ArticleId>
            <ArticleId IdType="pmc">PMC7385672</ArticleId>
            <ArticleId IdType="pubmed">32730555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A, et al.  Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Hear Fail [Internet] 2020;7:2440–2447. doi: 10.1002/ehf2.12805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ehf2.12805</ArticleId>
            <ArticleId IdType="pmc">PMC7307078</ArticleId>
            <ArticleId IdType="pubmed">32529795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fox SE, Li G, Akmatbekov A, Harbert JL, Lameira FS, Brown JQ, et al.  Unexpected Features of Cardiac Pathology in COVID-19 Infection. Circulation [Internet] 2020;142:1123–1125. doi: 10.1161/CIRCULATIONAHA.120.049465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049465</ArticleId>
            <ArticleId IdType="pubmed">32689809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Yang L, Nilsson-Payant B, Han Y, Jaffré F, Zhu J, et al. SARS-CoV-2 infected cardiomyocytes recruit monocytes by secreting CCL2. Res Sq [Preprint]. 2020 Nov 17:rs.3.rs-94634. 10.21203/rs.3.rs-94634/v1.</Citation>
        </Reference>
        <Reference>
          <Citation>Pérez-Bermejo JA, Kang S, Rockwood SJ, Simoneau CR, Joy DA, Ramadoss GN, et al. SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients. bioRxiv [Preprint]. 2020 Sep 12:2020.08.25.265561. 10.1101/2020.08.25.265561 Update in: Sci Transl Med. 2021 Mar 15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8128284</ArticleId>
            <ArticleId IdType="pubmed">33723017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al.  A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua bing li xue za zhi = Chinese J Pathol [Internet] 2020;49:411–417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32172546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, et al.  Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J [Internet] 2020;41:1861–1862. doi: 10.1093/eurheartj/ehaa286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehaa286</ArticleId>
            <ArticleId IdType="pmc">PMC7184339</ArticleId>
            <ArticleId IdType="pubmed">32267502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark DE, Parikh A, Dendy JM, Diamond AB, George-Durrett K, Fish FA, et al. COVID-19 myocardial pathology evaluated through scrEening cardiac magnetic resonance (COMPETE CMR). medRxiv [Preprint]. 2020 Sep 2:2020.08.31.20185140. 10.1101/2020.08.31.20185140 Update in: Circulation. 2020 Dec 17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7864610</ArticleId>
            <ArticleId IdType="pubmed">33332151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knight DS, Kotecha T, Razvi Y, Chacko L, Brown JT, Jeetley PS, et al.  COVID-19: Myocardial Injury in Survivors. Circulation [Internet] 2020;142:1120–1122. doi: 10.1161/CIRCULATIONAHA.120.049252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049252</ArticleId>
            <ArticleId IdType="pmc">PMC7492396</ArticleId>
            <ArticleId IdType="pubmed">32673505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) JAMA Cardiol [Internet] 2020;5:1265–1273. doi: 10.1001/jamacardio.2020.3557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId>
            <ArticleId IdType="pmc">PMC7385689</ArticleId>
            <ArticleId IdType="pubmed">32730619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trogen B, Gonzalez FJ, Shust GF. COVID-19-Associated Myocarditis in an Adolescent. Pediatr Infect Dis J [Internet] 2020;39:e204–e205. doi: 10.1097/INF.0000000000002788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0000000000002788</ArticleId>
            <ArticleId IdType="pubmed">32502128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet (London, England) [Internet] 2020;395:1516. doi: 10.1016/S0140-6736(20)30912-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30912-0</ArticleId>
            <ArticleId IdType="pmc">PMC7180035</ArticleId>
            <ArticleId IdType="pubmed">32334650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) JAMA Cardiol [Internet] 2020;5:819–824. doi: 10.1001/jamacardio.2020.1096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2020.1096</ArticleId>
            <ArticleId IdType="pmc">PMC7364333</ArticleId>
            <ArticleId IdType="pubmed">32219357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim I-C, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J [Internet] 2020;41:1859. doi: 10.1093/eurheartj/ehaa288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehaa288</ArticleId>
            <ArticleId IdType="pmc">PMC7184491</ArticleId>
            <ArticleId IdType="pubmed">32282027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luetkens JA, Homsi R, Dabir D, Kuetting DL, Marx C, Doerner J, et al.  Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis. J Am Heart Assoc [Internet] 2016;5:e003603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5015395</ArticleId>
            <ArticleId IdType="pubmed">27436306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemos ACB, do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, et al.  Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID) Thromb Res [Internet] 2020;196:359–366. doi: 10.1016/j.thromres.2020.09.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2020.09.026</ArticleId>
            <ArticleId IdType="pmc">PMC7503069</ArticleId>
            <ArticleId IdType="pubmed">32977137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res [Internet] 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId>
            <ArticleId IdType="pmc">PMC7054408</ArticleId>
            <ArticleId IdType="pubmed">32020029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England) [Internet] 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId>
            <ArticleId IdType="pmc">PMC7190303</ArticleId>
            <ArticleId IdType="pubmed">32423584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilt TJ, Kaka AS, MacDonald R, Greer N, Obley A, Duan-Porter W. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points. Ann Intern Med [Internet] 2021;174:209–220. doi: 10.7326/M20-5752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M20-5752</ArticleId>
            <ArticleId IdType="pmc">PMC7564604</ArticleId>
            <ArticleId IdType="pubmed">33017170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO Solidarity Trial Consortium. Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, et al.  Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med [Internet] 2021;384:497–511. doi: 10.1056/NEJMoa2023184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId>
            <ArticleId IdType="pmc">PMC7727327</ArticleId>
            <ArticleId IdType="pubmed">33264556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clementi N, Ferrarese R, Criscuolo E, Diotti RA, Castelli M, Scagnolari C, et al.  Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection. J Infect Dis [Internet] 2020;222:722–725. doi: 10.1093/infdis/jiaa350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiaa350</ArticleId>
            <ArticleId IdType="pmc">PMC7337790</ArticleId>
            <ArticleId IdType="pubmed">32559285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Forensic Sci Int. 2020;370:eabd4570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7857407</ArticleId>
            <ArticleId IdType="pubmed">32972995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Forensic Sci Int. 2020;370:eabd4585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7857397</ArticleId>
            <ArticleId IdType="pubmed">32972996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al.  Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet (London, England) [Internet] 2020;395:1695–1704. doi: 10.1016/S0140-6736(20)31042-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId>
            <ArticleId IdType="pmc">PMC7211500</ArticleId>
            <ArticleId IdType="pubmed">32401715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al.  Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med [Internet] 2021;9:196–206. doi: 10.1016/S2213-2600(20)30511-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30511-7</ArticleId>
            <ArticleId IdType="pmc">PMC7836724</ArticleId>
            <ArticleId IdType="pubmed">33189161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clin Infect Dis [Internet] 2020;71:732–739. doi: 10.1093/cid/ciaa237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId>
            <ArticleId IdType="pmc">PMC7108130</ArticleId>
            <ArticleId IdType="pubmed">32150618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ [Internet] 2020;369:m1849. doi: 10.1136/bmj.m1849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m1849</ArticleId>
            <ArticleId IdType="pmc">PMC7221473</ArticleId>
            <ArticleId IdType="pubmed">32409561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al.  Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med [Internet] 2020;383:2041–2052. doi: 10.1056/NEJMoa2019014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2019014</ArticleId>
            <ArticleId IdType="pmc">PMC7397242</ArticleId>
            <ArticleId IdType="pubmed">32706953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al.  Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA [Internet] 2020;324:2165–2176. doi: 10.1001/jama.2020.22240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.22240</ArticleId>
            <ArticleId IdType="pmc">PMC7653542</ArticleId>
            <ArticleId IdType="pubmed">33165621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al.  Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA [Internet] 2020;324:1317–1329. doi: 10.1001/jama.2020.17022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.17022</ArticleId>
            <ArticleId IdType="pmc">PMC7489418</ArticleId>
            <ArticleId IdType="pubmed">32876697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dequin P-F, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al.  Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA [Internet] 2020;324:1298–1306. doi: 10.1001/jama.2020.16761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.16761</ArticleId>
            <ArticleId IdType="pmc">PMC7489432</ArticleId>
            <ArticleId IdType="pubmed">32876689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CMP J, MEL F, FFA V, Sampaio VS, MAA A, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021 May 4;72(9):e373–81. 10.1093/cid/ciaa1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7454320</ArticleId>
            <ArticleId IdType="pubmed">32785710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA [Internet] 1994;271:1836–1843. doi: 10.1001/jama.1994.03510470040032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.1994.03510470040032</ArticleId>
            <ArticleId IdType="pubmed">8196140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med [Internet] 2016;44:275–281. doi: 10.1097/CCM.0000000000001402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCM.0000000000001402</ArticleId>
            <ArticleId IdType="pmc">PMC5378312</ArticleId>
            <ArticleId IdType="pubmed">26584195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol [Internet] 2020;2:e325–e331. doi: 10.1016/S2665-9913(20)30127-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(20)30127-2</ArticleId>
            <ArticleId IdType="pmc">PMC7252085</ArticleId>
            <ArticleId IdType="pubmed">32501454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ucciferri C, Auricchio A, Di Nicola M, Potere N, Abbate A, Cipollone F, et al.  Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol [Internet] 2020;2:e457–ee458. doi: 10.1016/S2665-9913(20)30167-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(20)30167-3</ArticleId>
            <ArticleId IdType="pmc">PMC7272172</ArticleId>
            <ArticleId IdType="pubmed">32835251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>•• Cremer PC, Sheng C, Sahoo D, Dugar S, Aguillon-Prada R, Hernandez-Montfort J, et al. Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in Sars-cov2 Associated Myocardial Injury With Heightened Inflammation (canakinumab in Covid-19 Cardiac Injury): Results From the Randomized Three C Study. Late-Breaking. Sci Abstr Featur Sci Abstr From Am Hear Assoc Sci Sess 2020 [Internet]. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000940. In patients with cardiac injury, this study showed that patients with high dose canakinumab were numerically more likely to demonstrate clinical recovery at 28 days.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIR.0000000000000940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malgie J, Schoones JW, Pijls BG. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2021 Jun 1;72(11):e742–9. 10.1093/cid/ciaa1445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7543350</ArticleId>
            <ArticleId IdType="pubmed">32964913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al.  Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med [Internet] 2021;181:41–51. doi: 10.1001/jamainternmed.2020.6252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2020.6252</ArticleId>
            <ArticleId IdType="pmc">PMC7577201</ArticleId>
            <ArticleId IdType="pubmed">33080002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al.  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med [Internet] 2020;383:2333–2344. doi: 10.1056/NEJMoa2028836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2028836</ArticleId>
            <ArticleId IdType="pmc">PMC7646626</ArticleId>
            <ArticleId IdType="pubmed">33085857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report. Unpubl Work. 2021;</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7953461</ArticleId>
            <ArticleId IdType="pubmed">33631065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA [Internet] 2020;324:460–470. doi: 10.1001/jama.2020.10044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.10044</ArticleId>
            <ArticleId IdType="pmc">PMC7270883</ArticleId>
            <ArticleId IdType="pubmed">32492084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al.  Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ [Internet] 2020;371:m3939. doi: 10.1136/bmj.m3939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m3939</ArticleId>
            <ArticleId IdType="pmc">PMC7578662</ArticleId>
            <ArticleId IdType="pubmed">33093056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv Prepr Serv Heal Sci [Internet]. 2020; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32817978.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
